Voyager Therapeutics Q3 2023 Earnings Report $5.58 +0.05 (+0.83%) As of 09:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Voyager Therapeutics EPS ResultsActual EPS-$0.59Consensus EPS -$0.58Beat/MissMissed by -$0.01One Year Ago EPSN/AVoyager Therapeutics Revenue ResultsActual Revenue$4.61 millionExpected Revenue$1.75 millionBeat/MissBeat by +$2.86 millionYoY Revenue GrowthN/AVoyager Therapeutics Announcement DetailsQuarterQ3 2023Date11/6/2023TimeN/AConference Call ResourcesVYGR Earnings History Voyager Therapeutics Earnings HeadlinesVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from BrokeragesFebruary 5 at 3:09 AM | americanbankingnews.comVoyager: Crossing The Blood-Brain Barrier, Competitors, And Investment RelevanceJanuary 30, 2025 | seekingalpha.comBiden activates Trump's "hidden" energy plan...While everyone's focused on OpenAI... Sam Altman just quietly dropped $577 million into something completely different. And it traces back to a mysterious executive order Trump signed two weeks before leaving office. Here's the fascinating part... Warren Buffett, known for avoiding new technologies, suddenly broke his own rule and jumped in... Bill Gates followed... Even the Perrodo family (worth $3.9 billion from oil) just redirected $262 million towards this. What could make these billionaires pivot so dramatically? The answer lies in Executive Order 13972...February 5, 2025 | Wealthpin Pro (Ad)Reviewing Kyverna Therapeutics (NASDAQ:KYTX) & Voyager Therapeutics (NASDAQ:VYGR)January 29, 2025 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Voyager Therapeutics (NASDAQ:VYGR)January 28, 2025 | americanbankingnews.comPositive Outlook for Voyager Therapeutics Driven by Promising CNS Gene Therapies and Innovative TRACER PlatformJanuary 27, 2025 | markets.businessinsider.comSee More Voyager Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Voyager Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Voyager Therapeutics and other key companies, straight to your email. Email Address About Voyager TherapeuticsVoyager Therapeutics (NASDAQ:VYGR), a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.View Voyager Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Palantir Stock Surges After Blockbuster Earnings: What's Next?Atlassian: Upside Still in Play After Impressive Earnings SpikeWhy Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent Dip Upcoming Earnings AstraZeneca (2/6/2025)Fortinet (2/6/2025)Amazon.com (2/6/2025)Linde (2/6/2025)Sumitomo Mitsui Financial Group (2/6/2025)ING Groep (2/6/2025)ConocoPhillips (2/6/2025)KKR & Co. Inc. (2/6/2025)Intercontinental Exchange (2/6/2025)Thomson Reuters (2/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
